In Segment C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, members will receive ABBV-744 and ruxolitinib. Individuals will get treatment right until disease progression or even the contributors are unable to tolerate the study drugs. Celastrol was recognized for a Myb inhibitor that suppressed C/EBPβ activity and https://abbv-744brd4inhibitormech02356.blogripley.com/32725370/a-review-of-abbv-744-in-combination-with-immunotherapy